U.S. pharmaceutical companies are expected to collect more revenue from COVID-19 vaccines in the third quarter than they did in the entire first half of the year, and that money should continue to grow.
U.S. pharmaceutical companies are expected to collect more revenue from COVID-19 vaccines in the third quarter than they did in the entire first half of the year, and that money should continue to grow.